COP:XETRA-CompuGroup Medical SE & Co. KGaA (EUR)

COMMON STOCK | Health Information Services | XETRA

Last Closing Price

EUR 37.28

Change

+0.78 (+2.14)%

Market Cap

EUR 1.91B

Volume

0.06M

Avg Analyst Target

EUR 64.07 (+71.87%)

Avg User Target

EUR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


COP Stock Forecast & Price:
Based on the CompuGroup Medical SE & Co. KGaA stock forecasts from 6 analysts, the average analyst target price for CompuGroup Medical SE & Co. KGaA is EUR 64.07 over the next 12 months. CompuGroup Medical SE & Co. KGaA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of CompuGroup Medical SE & Co. KGaA is Slightly Bearish, which is based on 5 positive signals and 9 negative signals. At the last closing, CompuGroup Medical SE & Co. KGaA’s stock price was EUR 37.28. CompuGroup Medical SE & Co. KGaA’s stock price has changed by +3.96% over the past week, +6.09% over the past month and -45.30% over the last year.

About CompuGroup Medical SE & Co. KGaA (COP:XETRA)

CompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and C ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NXU:XETRA Nexus AG

-1.60 (-2.56%)

EUR1.01B 53.78 21.42
AJ91:XETRA DocCheck AG

-0.45 (-3.04%)

EUR0.07B 10.79 4.42
M3V:XETRA MeVis Medical Solutions AG

N/A

EUR0.06B 10.95 9.81
IS8:XETRA ifa systems AG

N/A

EUR0.01B 884.00 7.39

ETFs Containing COP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.60% 40% F 6% F
Dividend Return 0.70% 50% F 14% F
Total Return -46.90% 40% F 6% F
Trailing 12 Months  
Capital Gain -44.36% 40% F 6% F
Dividend Return 0.75% 50% F 14% F
Total Return -43.61% 40% F 6% F
Trailing 5 Years  
Capital Gain -34.70% 40% F 14% F
Dividend Return 3.24% 50% F 17% F
Total Return -31.46% 40% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain 4.62% 40% F 49% F
Dividend Return 0.61% 60% D- 55% F
Total Return 5.23% 40% F 48% F
Risk Return Profile  
Volatility (Standard Deviation) 30.65% 80% B- 24% F
Risk Adjusted Return 17.05% 40% F 41% F
Market Capitalization 1.91B 100% A+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.64 60% D- 32% F
Price/Book Ratio 2.90 60% D- 32% F
Price / Cash Flow Ratio 11.54 40% F 34% F
EV/EBITDA 11.71 40% F 32% F
Management Effectiveness  
Return on Equity 11.18% 40% F 51% F
Return on Invested Capital 0.81% 20% F 26% F
Return on Assets 3.10% 40% F 51% F
Debt to Equity Ratio 2,900.47% 50% F 1% F
Technical Ratios  
Dividend Yield 1.32% 50% F 24% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.97 40% F 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector